PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia

Recruiting

Conditions: Acute Myeloid Leukemia

First Posted Date: 2022-01-12

Last Posted Date: 2024-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 165

Registration Number: NCT05189639

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

Phase 1

Withdrawn

Conditions: Healthy Participants

Interventions: Drug: [14C]PF-07321332

First Posted Date: 2022-01-05

Last Posted Date: 2022-01-31

Lead Sponsor: Pfizer

Registration Number: NCT05178654

Latin American Real-world Study in Acute Leukemia

Completed

Conditions: Acute Lymphoid Leukemia
Acute Myeloid Leukemia

First Posted Date: 2021-12-21

Last Posted Date: 2023-06-15

Lead Sponsor: Pfizer

Target Recruit Count: 589

Registration Number: NCT05166135

Locations: 🇦🇷
FUNDALEU - Fundacion para combatir la Leucemia, Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
🇧🇷
Hospital São Rafael, Salvador, Bahia, Brazil
🇦🇷
Hospital Privado Centro Medico de Cordoba S.A., Cordoba, Argentina

and more 11 locations

Patient Reported Health-Related Quality of Life Associated With COVID-19

Recruiting

Conditions: COVID-19
Coronavirus Disease 2019
Influenza

Interventions: Biological: COVID-19 Vaccine

First Posted Date: 2021-12-16

Last Posted Date: 2024-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 999

Registration Number: NCT05160636

Locations: 🇺🇸
CVS Health, Woonsocket, Rhode Island, United States

Crizotinib Continuation Clinical Study

Phase 4

Active, not recruiting

Conditions: IMT
NSCLC
ALCL

Interventions: Drug: crizotinib

First Posted Date: 2021-12-16

Last Posted Date: 2024-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT05160922

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Guangzhou Medical University., Guangzhou, China
🇨🇳
West China Hospital of Sichuan University, Wuhou District,Chengdu, Sichuan, China

and more 10 locations

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: PF-07081532
Drug: Placebo

First Posted Date: 2021-12-15

Last Posted Date: 2024-08-12

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT05158244

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Phase 3

Recruiting

Conditions: Migraine

Interventions: Drug: Rimegepant
Drug: Placebo

First Posted Date: 2021-12-14

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 640

Registration Number: NCT05156398

Locations: 🇯🇵
Tominaga Clinic, Naniwa-ku, Osaka-shi, Osaka, Japan
🇯🇵
Saitama Neuropsychiatric Institute, Chuo-ku Saitama-shi, Saitama, Japan
🇯🇵
Tokyo Headache Clinic, Shibuya-ku, Tokyo, Japan

and more 118 locations

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Completed

Conditions: Breast Cancer Metastatic

First Posted Date: 2021-12-13

Last Posted Date: 2024-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 847

Registration Number: NCT05155566

Locations: 🇦🇷
Pfizer country office, Buenos Aires, Argentina
🇬🇧
Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK, Bollington, Chesshire, United Kingdom

Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan

Completed

Conditions: Breast Cancer

First Posted Date: 2021-12-10

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 1170

Registration Number: NCT05153187

Locations: 🇯🇵
Pfizer Japan Inc., Tokyo, Japan

Lorlatinib Continuation Study

Phase 4

Active, not recruiting

Conditions: NSCLC
Non-Small-Cell Lung Cancer

Interventions: Drug: Lorlatinib

First Posted Date: 2021-12-06

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 74

Registration Number: NCT05144997

Locations: 🇺🇸
UC Irvine Health, Orange, California, United States
🇨🇳
The First affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China

and more 27 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy